SCHEMBL15935008

SCHEMBL15935008

Cc1ccn(-c2c(F)cncc2F)n1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
ATM Q13315 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
TDO2 P48775 1/20 0.41
HTT P42858 1/20 0.38
KCNN3 Q9UGI6 2/20 0.33
NOS1 P29475 1/20 0.32
KAT6A Q92794 4/20 0.32
TGFBR1 P36897 1/20 0.32
CYP46A1 Q9Y6A2 1/20 0.32
ATR Q13535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1813753 0.82 RAB9A (0.55) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL16201995 0.81 MAPT (0.47) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL5541828 0.78 RAB9A (0.48) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935040 0.77 MAPT (0.47) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL12532375 0.76 RAB9A (0.68) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL2690822 0.73 ELOVL1 (0.46) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL14412227 0.71 MAPT (0.58) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL16202104 0.70 MAPT (0.44) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL16202105 0.69 RAB9A (0.47) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL13078703 0.69 MAPT (0.52) MAPTRAB9ANPC1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 MAPT 4751/4885RAB9A 556/4885NPC1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.